BR112017010657A2 - cápsulas macias de calcifediol - Google Patents
cápsulas macias de calcifediolInfo
- Publication number
- BR112017010657A2 BR112017010657A2 BR112017010657-4A BR112017010657A BR112017010657A2 BR 112017010657 A2 BR112017010657 A2 BR 112017010657A2 BR 112017010657 A BR112017010657 A BR 112017010657A BR 112017010657 A2 BR112017010657 A2 BR 112017010657A2
- Authority
- BR
- Brazil
- Prior art keywords
- soft capsules
- calcifediol
- osteoarthritis
- vitamin
- deficiency
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Lubricants (AREA)
- Carbon And Carbon Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Paints Or Removers (AREA)
Abstract
a presente invenção refere-se a cápsulas macias de calcifediol, ao seu uso no tratamento ou prevenção de enfermidades relacionadas com a deficiência da vitamina d, tais como deficiência da vitamina d, desmineralização tais como hipocalcemia e hipofosfatemia, osteodistrofia renal, raquitismo, osteoporose, osteopenia, osteoartrite, osteoartrose, osteomalacia, hipoparatiroidismo, e enfermidade inflamatória do intestino, e ao seu processo de manufatura.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382042.8 | 2015-02-06 | ||
EP15382042.8A EP3053598A1 (en) | 2015-02-06 | 2015-02-06 | Calcifediol soft capsules |
PCT/EP2016/052458 WO2016124724A1 (en) | 2015-02-06 | 2016-02-05 | Calcifediol soft capsules |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017010657A2 true BR112017010657A2 (pt) | 2018-02-14 |
BR112017010657B1 BR112017010657B1 (pt) | 2022-10-11 |
Family
ID=52462260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017010657-4A BR112017010657B1 (pt) | 2015-02-06 | 2016-02-05 | Cápsulas moles de calcifediol |
Country Status (30)
Country | Link |
---|---|
US (1) | US10525018B2 (pt) |
EP (3) | EP3053598A1 (pt) |
JP (2) | JP6427270B2 (pt) |
KR (1) | KR101971384B1 (pt) |
CN (2) | CN112843014A (pt) |
AU (1) | AU2016214336B2 (pt) |
BR (1) | BR112017010657B1 (pt) |
CA (1) | CA2967170C (pt) |
CL (1) | CL2017001335A1 (pt) |
CO (1) | CO2017004545A2 (pt) |
CY (1) | CY1122976T1 (pt) |
DK (2) | DK3689380T3 (pt) |
EA (1) | EA034821B1 (pt) |
ES (2) | ES2941385T3 (pt) |
HR (1) | HRP20200859T1 (pt) |
HU (1) | HUE050133T2 (pt) |
LT (1) | LT3204047T (pt) |
MA (2) | MA52507A (pt) |
MD (1) | MD3204047T2 (pt) |
ME (1) | ME03739B (pt) |
MX (1) | MX367999B (pt) |
MY (1) | MY189432A (pt) |
PE (1) | PE20170911A1 (pt) |
PH (1) | PH12017501350A1 (pt) |
PL (1) | PL3204047T3 (pt) |
PT (1) | PT3204047T (pt) |
RS (2) | RS64166B1 (pt) |
SI (1) | SI3204047T1 (pt) |
WO (1) | WO2016124724A1 (pt) |
ZA (1) | ZA201703444B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
CN108542908A (zh) * | 2018-06-08 | 2018-09-18 | 唐飞 | 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用 |
CN109662953B (zh) * | 2019-02-18 | 2022-05-10 | 威海金思力生物科技股份有限公司 | 一种维生素d软胶囊及其制作方法 |
WO2021011538A1 (en) * | 2019-07-15 | 2021-01-21 | R.P. Scherer Technologies, Llc | Capsule dosage forms, methods of preparation and methods of use thereof |
CN113559079B (zh) * | 2020-04-28 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 一种软胶囊及其制备方法和用途 |
WO2022103635A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
WO2022224001A1 (en) | 2021-04-22 | 2022-10-27 | Faes Farma, S.A. | Universal dosage regime of 25-hydroxy vitamin d3 |
CN114159402A (zh) * | 2021-12-21 | 2022-03-11 | 湖州展望天明药业有限公司 | 一种不透明植物胶囊及其制备方法 |
CN114712505B (zh) * | 2022-03-10 | 2023-09-05 | 南方医科大学南方医院 | 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用 |
CN116270520A (zh) * | 2023-03-03 | 2023-06-23 | 正大制药(青岛)有限公司 | 一种维生素d胶囊型滴剂及其制备方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4532126A (en) * | 1982-05-07 | 1985-07-30 | R. P. Scherer Corporation | Masticatory soft elastic gelatin capsules and method for the manufacture thereof |
GB8305693D0 (en) | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
JPS6335411A (ja) | 1986-07-29 | 1988-02-16 | Tonen Sekiyukagaku Kk | 高純度合成石英の製造方法 |
US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
JPH04288016A (ja) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 活性型ビタミンd3類軟カプセル剤の製造方法 |
JPH054925A (ja) | 1991-06-27 | 1993-01-14 | Teikoku Chem Ind Corp Ltd | アルフアカルシドール軟カプセル製剤 |
JP2684587B2 (ja) | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
EP1208843B1 (en) * | 1999-08-31 | 2010-10-13 | Chugai Seiyaku Kabushiki Kaisha | Soft capsules |
US6251426B1 (en) | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
IL162213A0 (en) | 2001-12-03 | 2005-11-20 | Novacea Inc | Pharmaceutical compositions containing active vitamin d compounds |
US7632518B2 (en) * | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
US20030158264A1 (en) * | 2002-02-20 | 2003-08-21 | Ramachandran Radhakrishnan | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
AU2003230191A1 (en) | 2002-02-20 | 2003-09-09 | Strides Arcolab Limited | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
EP1494683A1 (en) | 2002-04-05 | 2005-01-12 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
US7438903B2 (en) | 2003-06-06 | 2008-10-21 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
PT103177A (pt) | 2003-09-24 | 2005-03-31 | Bioxell Spa | 1-alfa-fluoro-25-hidroxi-16,23e-dieno-26,27-bis-homo-20-epi-colecalciferol, seus sais ou esteres e sua utilizacao no fabrico de medicamentos |
US20050142185A1 (en) | 2003-12-29 | 2005-06-30 | Beleno Alfredo B. | Softgel formulations of bisphosphonates bone resorption inhibitors |
US20050152969A1 (en) | 2004-01-08 | 2005-07-14 | Chiprich Timothy B. | Colored liquid-filled soft capsules and method of manufacture thereof |
US20050175686A1 (en) | 2004-02-11 | 2005-08-11 | Ramachandran Radhakrishnan | Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule |
US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
GB2429916A (en) | 2004-06-07 | 2007-03-14 | Strides Arcolab Ltd | Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same |
EP1928471A2 (en) | 2005-09-26 | 2008-06-11 | Novacea, Inc. | Prevention and treatment of gastrointestinal and bladder disorders associated with chemotherapy or radiation therapy using active vitamin d compounds |
US20070098819A1 (en) * | 2005-11-02 | 2007-05-03 | Susan Thys-Jacobs | Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks |
ES2904546T3 (es) * | 2006-02-03 | 2022-04-05 | Opko Renal Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
US8501717B2 (en) * | 2007-02-09 | 2013-08-06 | Merck, Sharp & Dohme Corp. | Methods to treat and/or prevent mucositis |
DK2481400T3 (da) * | 2007-04-25 | 2014-09-29 | Opko Ip Holdings Ii Inc | Orale præparater med kontrolleret frigivelse omfattende en vitamin D-forbindelse og en voksagtig bærer |
CA2683628C (en) | 2007-04-25 | 2018-03-06 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
US8759328B2 (en) * | 2008-07-24 | 2014-06-24 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration |
WO2010075065A2 (en) | 2008-12-15 | 2010-07-01 | Banner Pharmacaps, Inc. | Methods for enhancing the release and absorption of water insoluble active agents |
WO2010117873A2 (en) | 2009-04-06 | 2010-10-14 | Banner Pharmacaps, Inc. | Progesterone solutions for increased bioavailability |
WO2012047098A1 (en) | 2010-10-04 | 2012-04-12 | Dishman Pharmaceuticals And Chemicals Ltd. | Encapsulated fat-soluble vitamin |
GB201216385D0 (en) | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
-
2015
- 2015-02-06 EP EP15382042.8A patent/EP3053598A1/en not_active Withdrawn
-
2016
- 2016-02-05 EP EP16702960.2A patent/EP3204047B1/en active Active
- 2016-02-05 PE PE2017000841A patent/PE20170911A1/es unknown
- 2016-02-05 MA MA052507A patent/MA52507A/fr unknown
- 2016-02-05 LT LTEP16702960.2T patent/LT3204047T/lt unknown
- 2016-02-05 ES ES20163569T patent/ES2941385T3/es active Active
- 2016-02-05 PT PT167029602T patent/PT3204047T/pt unknown
- 2016-02-05 ME MEP-2020-108A patent/ME03739B/me unknown
- 2016-02-05 AU AU2016214336A patent/AU2016214336B2/en active Active
- 2016-02-05 DK DK20163569.5T patent/DK3689380T3/da active
- 2016-02-05 WO PCT/EP2016/052458 patent/WO2016124724A1/en active Application Filing
- 2016-02-05 EP EP20163569.5A patent/EP3689380B1/en not_active Revoked
- 2016-02-05 US US15/524,174 patent/US10525018B2/en active Active
- 2016-02-05 CA CA2967170A patent/CA2967170C/en active Active
- 2016-02-05 SI SI201630778T patent/SI3204047T1/sl unknown
- 2016-02-05 RS RS20230331A patent/RS64166B1/sr unknown
- 2016-02-05 HU HUE16702960A patent/HUE050133T2/hu unknown
- 2016-02-05 ES ES16702960T patent/ES2738642T3/es active Active
- 2016-02-05 EA EA201791097A patent/EA034821B1/ru unknown
- 2016-02-05 MY MYPI2017702240A patent/MY189432A/en unknown
- 2016-02-05 DK DK16702960.2T patent/DK3204047T3/da active
- 2016-02-05 CN CN202110038958.XA patent/CN112843014A/zh active Pending
- 2016-02-05 MD MDE20170056T patent/MD3204047T2/ro unknown
- 2016-02-05 MX MX2017006272A patent/MX367999B/es active IP Right Grant
- 2016-02-05 MA MA41058A patent/MA41058B1/fr unknown
- 2016-02-05 BR BR112017010657-4A patent/BR112017010657B1/pt active IP Right Grant
- 2016-02-05 JP JP2017525563A patent/JP6427270B2/ja active Active
- 2016-02-05 RS RS20200628A patent/RS60467B1/sr unknown
- 2016-02-05 PL PL16702960T patent/PL3204047T3/pl unknown
- 2016-02-05 CN CN201680004162.XA patent/CN106999441B/zh active Active
- 2016-02-05 KR KR1020177012947A patent/KR101971384B1/ko active IP Right Review Request
-
2017
- 2017-05-05 CO CONC2017/0004545A patent/CO2017004545A2/es unknown
- 2017-05-18 ZA ZA2017/03444A patent/ZA201703444B/en unknown
- 2017-05-24 CL CL2017001335A patent/CL2017001335A1/es unknown
- 2017-07-28 PH PH12017501350A patent/PH12017501350A1/en unknown
-
2018
- 2018-07-27 JP JP2018141114A patent/JP6697779B2/ja active Active
-
2020
- 2020-05-28 HR HRP20200859TT patent/HRP20200859T1/hr unknown
- 2020-05-28 CY CY20201100484T patent/CY1122976T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017010657A2 (pt) | cápsulas macias de calcifediol | |
CL2016001154A1 (es) | Composiciones para prevenir o tratar alergias en infantes a partir de o alimentados por madres no secretoras. | |
CL2017003073A1 (es) | Inhibidores de tirosina-cinasas | |
CL2018001549A1 (es) | Mezcla de hmos | |
BR112017008284A2 (pt) | bifidobactérias ativadas e métodos para uso das mesmas | |
BR112017006464A2 (pt) | bloqueio de cd73 | |
BR112017022001A2 (pt) | método para preparação da forma silico-aluminada da estrutura de zeólito aei com altos rendimentos e sua aplicação na catálise. | |
GT201300123A (es) | Sal(es) de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-(2,3-d)-pirimidin-6-carboxilico y procesos para su elaboracion | |
BR112017013691A2 (pt) | composição compreendendo um polímero em multiestágio, seu método de preparação e seu uso | |
BR112018001260A2 (pt) | mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição. | |
BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
BR112016025876A8 (pt) | composição, processos para preparar uma microcápsula e uma forma de dosagem unitária, forma de dosagem unitária, microcápsula, produto, uso de uma composição, e, método para tratar uma condição associada à vitamina k1 ou k2 | |
SV2017005412A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
FR3029778B1 (fr) | Composition cosmetique comprenant des alpha-olefine sulfonates lineaires, des tensioactifs anioniques et des tensioactifs non ioniques et/ou ampho-teres, et procede de traitement cosmetique | |
CO2017002312A2 (es) | Compuestos bicíclicos sustituidos | |
BR112017007205A2 (pt) | mono- e diésteres de cadeia longa de 2,5-di(hidróximetil)tetra-hidrofurano, seu uso e produção. | |
BR112017019750A2 (pt) | processo para preparação de uma forma cristalina de menaquinol, forma cristalina de menaquinol, processo para preparação de uma forma sólida do menaquinol, composição farmacêutica ou nutracêutica e uso da forma cristalina de menaquinol | |
BR112018005871A2 (pt) | produção de composições de fosfato de cálcio | |
PE20160117A1 (es) | Composicion antirregurgitacion que mantiene la motilidad intestinal | |
ECSP17011672A (es) | Formulación en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida | |
GT201800102A (es) | Polipéptidos que inhiben cd4ol | |
BR112017004325A2 (pt) | composição nutricional para uso na promoção da maturação e/ou do reparo do intestino e/ou do fígado | |
Nobre et al. | Autopercepção de competências de crianças em situação de vulnerabilidade social assistidas e não assistidas por projetos sociais esportivos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2016, OBSERVADAS AS CONDICOES LEGAIS |